AT&T, Verizon and BlueBird satellites

Gene therapy maker bluebird bio on Friday agreed to be taken private by Carlyle and SK Capital Partners at a discount, ending ...
(NASDAQ:BLUE – Get Free Report) had its target price dropped by analysts at Wells Fargo & Company from $40.00 to $5.00 in a ...
Bluebird bio (BLUE) shares continued their downward descent Monday following news that the company plans to be taken private through a deal valued at up to $96M. Read more here.
Lafayette Consolidated Government’s Traffic, Roads, and Bridges Department has planned a traffic signal outage at Camellia ...
There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...
The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...
Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...
Bluebird Bio announced it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...
JPMorgan upgraded Bluebird Bio (BLUE) to Neutral from Underweight without a price target after the company entered into a definitive agreement ...
Wild Pink will never be mistaken for Spinal Tap, but the New York City band’s penchant for sprinkling some sarcasm throughout ...